| |
It's rare to see a small biotech actually run the full gauntlet and come out the other side. One company I flagged yesterday just launched its first product and is showing fresh signs of life. I'm keeping a close eye on it to see how this next phase plays out. | TODAY'S TOP ALERT! | Citius Oncology (Nasdaq: CTOR) | | 👉 CTOR is TODAY'S #1 ALERT 👈 | Hey Gang, Jeff Bishop here, | The biopharma space is tough. | It's expensive to develop a drug and expensive to get it to the clinical stage. Once it's there, more than 90% of all new drugs fail during their clinical trials, and it can take many years for the drugs that do advance. | For startup companies, that means a long time to wait for revenue that may never come. | My top "tactical trade" idea today is a company that has run the gauntlet and just debuted its first commercial product this month. | 💥Have a look at Citius Oncology (CTOR) on your favorite trading platform. | The company is a spinoff from Citius Pharmaceuticals (CTXR), a company I've alerted several times over the past year. | CTOR went public via SPAC merger in August 2024, and its stock has been volatile ever since. | The company's main asset is LYMPHIR, which received its first FDA approval in August 2024 for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. | CTOR has had to raise a good bit of capital for its pre-launch activities, but along the way it has "secured distribution service agreements with leading global providers." | Finally, on December 1, CTOR announced the commercial launch of LYMPHIR. | In the announcement, CTOR noted the drug "is entering a growing U.S. market valued at over $400 million, with further upside opportunities through international market access and potential expanded indications in the future." [emphasis added] | That news led to a 33% intraday surge in the stock price, but if you look at the chart, you'll see that the stock pulled back from there… | That was due in part to an $18 million at-the-market registered direct offering at $1.09 per share that closed on December 10. | With that capital raise behind it, and its lead asset now in the commercial stage, I first alerted CTOR before the bell yesterday and it surged into double-digit territory: | | And that was amid a broader market meltdown, with the Nasdaq plummeting 1.8% by the close. | I'm watching CTOR closely again today because the stock is green again in the pre-market as of this writing, and I think this bottom-bounce has room to run from here. 🏃🏼 | 👉 CTOR is TODAY'S #1 ALERT* 👈 | As mentioned, CTOR's LYMPHIR has received FDA approval for relapsed or refractory cutaneous T-cell lymphoma (CTCL), a tough blood-related cancer. | | CTOR estimates the addressable U.S. market at $400 million. | It notes that persistent/recurrent CTCL requires systemic therapy, and that heretofore, there have been limited systemic treatment options available. | On October 20, CTOR announced an expanded distribution agreement with McKesson Corporation, "one of the largest pharmaceutical distributors and healthcare services companies in North America." | That agreement meant that CTOR's U.S. distribution network now includes "all three of the largest pharmaceutical distributors in the country." | Also in October, CTOR said it was "actively engaging with regional distribution partners" to make LYMPHIR available to eligible patients "through country-specific Named Patient Programs (NPPs) in Europe, South America and the Middle East." | For context, "Named Patient Programs, also known as early access programs, are formally recognized pathways designed to give patients earlier access to promising new medicines in advance of full marketing authorization and commercial availability in markets outside the United States." | Interestingly, in November, CTOR revealed it has teamed up with Verix — "a leader in AI-powered commercial optimization technology for the life sciences sector" — to support LYMPHIR's commercial launch. | Verix's Tovana platform "integrates advanced analytics, real-world claims data, and machine learning to help inform Citius Oncology's commercial strategy and enable real-time field execution." | In sum, CTOR has now: | Entered a multi-hundred million market with limited competition
Built a major distributor network ahead of launch
Pursued early international access programs to expand patient reach, and Is using AI and data analytics to power launch execution
| Beyond CTCL, CTOR has teamed up with the University of Pittsburgh for an investigator-initiated trial that's underway to evaluate LYMPHIR "for potential use as an immunooncology therapy in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors." | The trial has turned out encouraging preliminary results including a 27% overall response rate (ORR) and a 33% clinical benefit rate. | Separately, the University of Minnesota is exploring LYMPHIR in combination with CAR T therapies in a Phase I trial with preliminary results anticipated in Q1 2026. | On October 16, Maxim Group reiterated a BUY rating with a $6 price target — 417% upside from yesterday's closing price. | As you do your own research on CTOR, be sure to check out this investor presentation released this month, as well as the company website. | As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. | Please read the full disclaimer at the bottom of this email as well, so you are aware of our compensation and other conflicts of interest, as well as additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration. | Bottom line: CTOR debuted its first commercial product this month, targeting a $400 million market opportunity. | Its stock surged into double-digit territory yesterday, and I'm watching it closely today to see if this bottom bounce is just getting started. | 💥Lock into CTOR for all the action! | To Your Success, |  | Jeff Bishop |
| | DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/ | *ISSUER-SPONSORED CONTENT: Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." | Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received sixty five thousand dollars (cash) from Citius Oncology (via Sica Media) for advertising Citius Oncology for a three day marketing program starting on December 17, 2025. | It might seem obvious, but while our client claims not to own any shares in Citius Oncology, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case. | Now, diving right into Citius Oncology might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep's with the SEC, any state securities regulatory authority, or any self-regu1atory organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
|
|
Tidak ada komentar:
Posting Komentar